Abstract Background and aims Bempedoic Acid (BA) is a novel Lipid-Lowering Therapy
(LLT). We performed a systematic review and meta-analysis to assess the efficacy and …

Bempedoic Acid (BA) is the new addition to lipid-lowering medications. This systematic
review and meta-analysis of randomized controlled trials (RCTs) assess the clinical efficacy …

Background Bempedoic acid (BA) is a novel lipid‐lowering drug. We performed a systematic
review and meta‐analysis on efficacy and safety of BA compared with standard treatment in …

Aim Bempedoic acid is a novel oral drug, which has been increasingly researched to play
an important role in the treatment of hypercholesterolemia recently. However, results from …

Objectives Bempedoic acid (BA) is a novel oral low-density lipoprotein cholesterol lowering
drug. This systematic review and meta-analysis aims to assess efficacy and safety for clinical …

Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been
approved by the European Medicinal Agency and Food and Drug Administration and has …

Aims Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular
mortality and morbidity. Bempedoic acid represents a promising novel lipid-modifying agent …

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by
guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its …

Aim This systematic review and meta-analysis was conducted to synthesize the efficacy and
safety of bempedoic acid in patients requiring lipid-lowering therapy. Methods PubMed …

Background Statins reduce LDL cholesterol and cardiovascular events among those with or
without diabetes but have been reported to increase new-onset diabetes. The CLEAR …